Q1 EPS Forecast for Halozyme Therapeutics Raised by Analyst

Halozyme Therapeutics, Inc. (NASDAQ:HALO) – Analysts at Zacks Research raised their Q1 2027 EPS estimates for Halozyme Therapeutics in a research report issued to clients and investors on Monday, February 2nd. Zacks Research analyst Team now anticipates that the biopharmaceutical company will post earnings of $1.63 per share for the quarter, up from their previous forecast of $1.55. The consensus estimate for Halozyme Therapeutics’ current full-year earnings is $4.73 per share.

Halozyme Therapeutics (NASDAQ:HALO) last posted its earnings results on Monday, November 3rd. The biopharmaceutical company reported $1.72 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.63 by $0.09. Halozyme Therapeutics had a net margin of 47.91% and a return on equity of 156.95%. The company had revenue of $354.26 million during the quarter, compared to analysts’ expectations of $339.18 million. During the same quarter last year, the company posted $1.27 EPS. Halozyme Therapeutics’s quarterly revenue was up 22.1% compared to the same quarter last year.

HALO has been the subject of several other reports. The Goldman Sachs Group reissued a “sell” rating and set a $56.00 price target on shares of Halozyme Therapeutics in a report on Thursday, December 4th. Morgan Stanley lowered their price objective on Halozyme Therapeutics from $80.00 to $79.00 and set an “overweight” rating on the stock in a research report on Monday, October 20th. Citizens Jmp lifted their target price on Halozyme Therapeutics from $91.00 to $92.00 and gave the stock a “market outperform” rating in a report on Tuesday, November 4th. Wall Street Zen upgraded shares of Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 31st. Finally, Leerink Partners raised shares of Halozyme Therapeutics from an “underperform” rating to a “market perform” rating and set a $70.00 price target on the stock in a research report on Tuesday, October 14th. Seven investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $78.80.

Halozyme Therapeutics Stock Up 1.9%

Halozyme Therapeutics stock opened at $77.93 on Tuesday. The company’s 50-day moving average price is $69.12 and its two-hundred day moving average price is $68.84. The company has a quick ratio of 1.37, a current ratio of 1.59 and a debt-to-equity ratio of 1.59. The stock has a market cap of $9.16 billion, a P/E ratio of 16.41, a P/E/G ratio of 0.32 and a beta of 0.97. Halozyme Therapeutics has a twelve month low of $47.50 and a twelve month high of $79.50.

Institutional Investors Weigh In On Halozyme Therapeutics

Large investors have recently modified their holdings of the business. DLD Asset Management LP raised its holdings in shares of Halozyme Therapeutics by 20.0% during the 3rd quarter. DLD Asset Management LP now owns 30,000,000 shares of the biopharmaceutical company’s stock worth $2,200,200,000 after buying an additional 5,000,000 shares in the last quarter. Arrowstreet Capital Limited Partnership grew its position in Halozyme Therapeutics by 29.5% in the third quarter. Arrowstreet Capital Limited Partnership now owns 3,290,665 shares of the biopharmaceutical company’s stock valued at $241,337,000 after acquiring an additional 749,484 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in Halozyme Therapeutics by 3.2% during the third quarter. Dimensional Fund Advisors LP now owns 2,078,426 shares of the biopharmaceutical company’s stock worth $152,431,000 after acquiring an additional 63,699 shares in the last quarter. Federated Hermes Inc. lifted its holdings in shares of Halozyme Therapeutics by 294.1% in the third quarter. Federated Hermes Inc. now owns 1,450,704 shares of the biopharmaceutical company’s stock worth $106,395,000 after acquiring an additional 1,082,638 shares during the last quarter. Finally, LSV Asset Management boosted its stake in shares of Halozyme Therapeutics by 0.9% in the 3rd quarter. LSV Asset Management now owns 1,266,027 shares of the biopharmaceutical company’s stock valued at $92,850,000 after purchasing an additional 10,787 shares in the last quarter. Institutional investors and hedge funds own 97.79% of the company’s stock.

Insider Activity

In other Halozyme Therapeutics news, Director Bernadette Connaughton sold 2,000 shares of the stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $70.25, for a total transaction of $140,500.00. Following the sale, the director directly owned 40,123 shares in the company, valued at $2,818,640.75. This represents a 4.75% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Helen Torley sold 16,569 shares of the business’s stock in a transaction that occurred on Monday, December 1st. The shares were sold at an average price of $68.92, for a total transaction of $1,141,935.48. Following the completion of the transaction, the chief executive officer owned 708,719 shares of the company’s stock, valued at $48,844,913.48. The trade was a 2.28% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 41,398 shares of company stock valued at $2,861,352 in the last ninety days. 2.40% of the stock is currently owned by company insiders.

Key Halozyme Therapeutics News

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Zacks Research raised multiple quarterly and annual EPS forecasts (notably FY2026 to $7.43 from $6.22 and FY2027 to $8.18 from $7.57), reflecting stronger forward profit expectations that can support a higher valuation. See MarketBeat summary of the Zacks notes. MarketBeat: HALO coverage
• Positive Sentiment: Zacks also lifted several near‑term quarter estimates (Q1–Q4 2026 and multiple quarters in 2027), signalling anticipated stronger revenue/earnings momentum that likely helped investor sentiment. See MarketBeat summary of the Zacks notes. MarketBeat: HALO coverage
• Positive Sentiment: Coverage highlighting Halozyme as an attractive long‑term/value investment (Zacks style score write‑up) bolsters the buy case for value‑oriented investors. Why Halozyme is a Top Value Stock (Zacks)
• Positive Sentiment: An investor piece arguing that recent acquisitions position Halozyme for longer‑term growth supports the strategic narrative beyond near‑term numbers and may attract growth investors. Halozyme: Key Acquisitions (Seeking Alpha)
• Neutral Sentiment: Zacks’ reports reiterate a wide range of forward estimates — consensus figures cited in summaries differ from Zacks’ own upgraded forecasts — so investors should watch upcoming company disclosures for confirmation. MarketBeat: HALO coverage
• Negative Sentiment: One small downgrade: Zacks trimmed Q3 2027 EPS slightly (from $2.02 to $1.99) — a minor data point but a reminder that not every quarter was raised. MarketBeat: HALO coverage

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.